Uniqure B.V. (QURE) 25.17 $QURE
How ARM's Edward Lanphier Is Fighting For Cell Therapy Cures That Save Patients And Portfolios
Life Sciences Report - Seeking Alpha - Fri Mar 20, 6:52AM CDT
Stem cell, gene therapy and genetically modified cell therapy companies have begun to attract serious capital from investors who understand biotechnology and have the wherewithal to move products into the clinic and into the market. But battles still...
BLUE: 123.89 (+9.48), QURE: 25.17 (+0.08), SGMO: 15.86 (+0.32), JUNO: 60.75 (+4.15), ATHX: 2.86 (-0.06), NVS: 101.31 (+0.91)
What's in Store for Juno Therapeutics this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 16, 9:40AM CDT
Juno Therapeutics (JUNO) is expected to report fourth quarter 2014 results on Mar 18.
QURE: 25.17 (+0.08), CPRX: 4.20 (+0.01), JUNO: 60.75 (+4.15)
Will BioDelivery Sciences (BDSI) Impress this Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 13, 10:10AM CDT
BioDelivery Sciences (BDSI) is expected to report fourth quarter 2014 results on Mar 16.
BDSI: 10.51 (-3.38), ENDP: 91.53 (+1.49), QURE: 25.17 (+0.08), CPRX: 4.20 (+0.01)
Xenon Pharmaceuticals Reports 2014 Financial Results and Provides Corporate Update
GlobeNewswire - Thu Mar 12, 3:00PM CDT
Progress in Partnered Programs and Proprietary Development Pipeline
QURE: 25.17 (+0.08), XENE: 17.14 (+0.39), ROG: 81.93 (+1.56), TEVA: 62.52 (+0.54)
uniQure (QURE) in Focus: Stock Gains 5.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 27, 8:11AM CST
uniQure N.V. (QURE) was a big mover last session, as the company saw its shares rise by nearly 6% on the day.
QURE: 25.17 (+0.08), AFFX: 12.86 (+0.15)
Makers of pricey drugs working on new payment model
Seeking Alpha - at Seeking Alpha - Thu Feb 19, 9:10AM CST
ABT: 47.08 (+0.30), BIIB: 431.62 (+1.75), BMRN: 129.13 (+0.35), PFE: 35.00 (+0.47), SGMO: 15.86 (+0.32), AMGN: 164.30 (+1.71), LLY: 73.87 (+0.29), BMY: 65.76 (+0.50), GSK: 47.20 (+0.18), CELG: 120.02 (+1.34), JNJ: 101.55 (+1.21), QURE: 25.17 (+0.08), GILD: 100.69 (-0.31), BAX: 68.76 (+0.21), MRK: 58.34 (+0.59), AZN: 69.94 (-0.13), NVS: 101.31 (+0.91)
uniQure to Present at the at the Leerink Partners Global Healthcare Conference
GlobeNewswire - Fri Feb 06, 4:48AM CST
uniQure to Present at the at the Leerink Partners Global Healthcare Conference
QURE: 25.17 (+0.08)
Nasdaq stocks posting largest percentage increases
AP - Wed Jan 21, 5:01PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
NFLX: 422.57 (+7.80), WATT: 9.84 (-0.09), EXPR: 16.47 (+0.28), AGRX: 9.36 (+0.13), QURE: 25.17 (+0.08), ASPS: 13.11 (-0.26), MCEP: 5.45 (-0.08), SCMP: 15.46 (+0.96), GWGH: 7.36 (-0.09), FANG: 77.63 (+2.46)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Jan 14, 11:43AM CST
BEBE: 3.65 (+0.02), MDLY: 11.92 (+0.23), ZIOP: 11.61 (+0.17), GME: 37.69 (-0.67), FCX: 19.38 (+0.58), BGC: 17.39 (+0.23), HBM: 8.37 (+0.11), XON: 46.30 (+3.30), BBEP: 5.55 (-0.35), PES: 4.92 (+0.03), AAMC: 187.05 (-3.95), DWCH: 6.81 (-0.08), SMSI: 1.30 (unch), ETRM: 0.94 (-0.02), FLML: 18.02 (+0.02), EEI: 8.80 (-0.20), FCSC: 4.34 (+0.23), QURE: 25.17 (+0.08), ERII: 2.59 (-0.05), KONE: 2.76 (-0.05)
Treeway Announces License and Collaboration Agreement with uniQure to Develop a Gene Therapy for Amyotrophic Lateral Sclerosis (ALS)
CNW Group - Wed Jan 14, 7:53AM CST
Treeway B.V., founded by entrepreneurs Bernard Muller and Robbert Jan Stuit, both diagnosed with ALS, have announced a collaboration with uniQure N.V., a leading gene therapy company, (NASDAQ:QURE), to develop a gene therapy treatment for ALS.
QURE: 25.17 (+0.08)
New finance chief at uniQure
Seeking Alpha - at Seeking Alpha - Fri Jan 09, 7:04AM CST
QURE: 25.17 (+0.08)
uniQure Appoints Matthew Kapusta as Chief Financial Officer
GlobeNewswire - Fri Jan 09, 4:08AM CST
uniQure N.V. (Nasdaq: QURE), a leader in human gene therapy, today announced that Matthew Kapusta has joined uniQure's management team as Chief Financial Officer effective January 1, 2015. Mr. Kapusta brings to the Company nearly 20 years of life science industry experience from investment banking and finance, as well as corporate development positions. In addition, uniQure announced the following changes to its Supervisory Board: Francois Meyer, a member of the Supervisory Boards of uniQure and its predecessor company AMT since 2010, and Sander Slootweg, Managing Partner of Forbion Capital Partners and Supervisory Board Member from 2006 to 2008 and again starting in 2012, will step down from the Supervisory Board. Philip Astley-Sparke, who has overseen uniQure's U.S. operations over the past two years, will be nominated for appointment to the Supervisory Board and will pass his operational responsibilities to Mr. Kapusta, who will be based in uniQure's Massachusetts manufacturing facility. Additionally, Prof. Hugo Katus, who is recognized as one of the leading heart surgeons and clinicians worldwide, has agreed to be nominated for appointment to the Supervisory Board. These changes are intended to add relevant breadth of experience and independence to the uniQure Supervisory Board.
QURE: 25.17 (+0.08), ANGO: 17.74 (+0.13)
Ackman Short Keeps Looking Better As Herbalife Takes A Dive
at The Street - Mon Jan 05, 2:46PM CST
Voltari Corp (NASDAQ:VLTC), Kite Pharma Inc (NASDAQ:KITE) and Uniqure NV (NASDAQ:QURE) are approaching market close in the green this Monday. In the red are Laredo Petroleum Inc (NYSE:LPI), Herbali...
HLF: 42.72 (-0.45), QURE: 25.17 (+0.08), KITE: 59.98 (+0.20), VLTC: 0.85 (+0.02), LPI: 13.21 (+0.46)
uniQure N.V. (QURE) Jumps: Stock Adds 6.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 7:51AM CST
uniQure N.V. (QURE) was a big mover last session, as its shares rose over 6% on the day.
QURE: 25.17 (+0.08), ANIP: 62.93 (+0.99), ILMN: 187.62 (+0.45), AFFX: 12.86 (+0.15)
uniQure to Present at the Oppenheimer 25th Healthcare Conference - NYC
GlobeNewswire - Fri Dec 05, 4:09AM CST
uniQure N.V. (Nasdaq: QURE), a leader in human gene therapy, today announced that its management will present at the Oppenheimer 25th Healthcare Conference - NYC, to be held December 10-11, 2014, at The Crowne Plaza Hotel in New York City, NY, USA.
QURE: 25.17 (+0.08)
uniQure reports Q3 results
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 7:37AM CST
QURE: 25.17 (+0.08)
How ARM's Edward Lanphier Is Fighting For Cell Therapy Cures That Save Patients And Portfolios
Life Sciences Report - Seeking Alpha - Fri Mar 20, 6:52AM CDT
Stem cell, gene therapy and genetically modified cell therapy companies have begun to attract serious capital from investors who understand biotechnology and have the wherewithal to move products into the clinic and into the market. But battles still...
BLUE: 123.89 (+9.48), QURE: 25.17 (+0.08), SGMO: 15.86 (+0.32), JUNO: 60.75 (+4.15), ATHX: 2.86 (-0.06), NVS: 101.31 (+0.91)
What's in Store for Juno Therapeutics this Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 16, 9:40AM CDT
Juno Therapeutics (JUNO) is expected to report fourth quarter 2014 results on Mar 18.
QURE: 25.17 (+0.08), CPRX: 4.20 (+0.01), JUNO: 60.75 (+4.15)
Will BioDelivery Sciences (BDSI) Impress this Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 13, 10:10AM CDT
BioDelivery Sciences (BDSI) is expected to report fourth quarter 2014 results on Mar 16.
BDSI: 10.51 (-3.38), ENDP: 91.53 (+1.49), QURE: 25.17 (+0.08), CPRX: 4.20 (+0.01)
Xenon Pharmaceuticals Reports 2014 Financial Results and Provides Corporate Update
GlobeNewswire - Thu Mar 12, 3:00PM CDT
Progress in Partnered Programs and Proprietary Development Pipeline
QURE: 25.17 (+0.08), XENE: 17.14 (+0.39), ROG: 81.93 (+1.56), TEVA: 62.52 (+0.54)
uniQure (QURE) in Focus: Stock Gains 5.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 27, 8:11AM CST
uniQure N.V. (QURE) was a big mover last session, as the company saw its shares rise by nearly 6% on the day.
QURE: 25.17 (+0.08), AFFX: 12.86 (+0.15)
Makers of pricey drugs working on new payment model
Seeking Alpha - at Seeking Alpha - Thu Feb 19, 9:10AM CST
ABT: 47.08 (+0.30), BIIB: 431.62 (+1.75), BMRN: 129.13 (+0.35), PFE: 35.00 (+0.47), SGMO: 15.86 (+0.32), AMGN: 164.30 (+1.71), LLY: 73.87 (+0.29), BMY: 65.76 (+0.50), GSK: 47.20 (+0.18), CELG: 120.02 (+1.34), JNJ: 101.55 (+1.21), QURE: 25.17 (+0.08), GILD: 100.69 (-0.31), BAX: 68.76 (+0.21), MRK: 58.34 (+0.59), AZN: 69.94 (-0.13), NVS: 101.31 (+0.91)
uniQure to Present at the at the Leerink Partners Global Healthcare Conference
GlobeNewswire - Fri Feb 06, 4:48AM CST
uniQure to Present at the at the Leerink Partners Global Healthcare Conference
QURE: 25.17 (+0.08)
Nasdaq stocks posting largest percentage increases
AP - Wed Jan 21, 5:01PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
NFLX: 422.57 (+7.80), WATT: 9.84 (-0.09), EXPR: 16.47 (+0.28), AGRX: 9.36 (+0.13), QURE: 25.17 (+0.08), ASPS: 13.11 (-0.26), MCEP: 5.45 (-0.08), SCMP: 15.46 (+0.96), GWGH: 7.36 (-0.09), FANG: 77.63 (+2.46)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Jan 14, 11:43AM CST
BEBE: 3.65 (+0.02), MDLY: 11.92 (+0.23), ZIOP: 11.61 (+0.17), GME: 37.69 (-0.67), FCX: 19.38 (+0.58), BGC: 17.39 (+0.23), HBM: 8.37 (+0.11), XON: 46.30 (+3.30), BBEP: 5.55 (-0.35), PES: 4.92 (+0.03), AAMC: 187.05 (-3.95), DWCH: 6.81 (-0.08), SMSI: 1.30 (unch), ETRM: 0.94 (-0.02), FLML: 18.02 (+0.02), EEI: 8.80 (-0.20), FCSC: 4.34 (+0.23), QURE: 25.17 (+0.08), ERII: 2.59 (-0.05), KONE: 2.76 (-0.05)
Treeway Announces License and Collaboration Agreement with uniQure to Develop a Gene Therapy for Amyotrophic Lateral Sclerosis (ALS)
CNW Group - Wed Jan 14, 7:53AM CST
Treeway B.V., founded by entrepreneurs Bernard Muller and Robbert Jan Stuit, both diagnosed with ALS, have announced a collaboration with uniQure N.V., a leading gene therapy company, (NASDAQ:QURE), to develop a gene therapy treatment for ALS.
QURE: 25.17 (+0.08)
New finance chief at uniQure
Seeking Alpha - at Seeking Alpha - Fri Jan 09, 7:04AM CST
QURE: 25.17 (+0.08)
uniQure Appoints Matthew Kapusta as Chief Financial Officer
GlobeNewswire - Fri Jan 09, 4:08AM CST
uniQure N.V. (Nasdaq: QURE), a leader in human gene therapy, today announced that Matthew Kapusta has joined uniQure's management team as Chief Financial Officer effective January 1, 2015. Mr. Kapusta brings to the Company nearly 20 years of life science industry experience from investment banking and finance, as well as corporate development positions. In addition, uniQure announced the following changes to its Supervisory Board: Francois Meyer, a member of the Supervisory Boards of uniQure and its predecessor company AMT since 2010, and Sander Slootweg, Managing Partner of Forbion Capital Partners and Supervisory Board Member from 2006 to 2008 and again starting in 2012, will step down from the Supervisory Board. Philip Astley-Sparke, who has overseen uniQure's U.S. operations over the past two years, will be nominated for appointment to the Supervisory Board and will pass his operational responsibilities to Mr. Kapusta, who will be based in uniQure's Massachusetts manufacturing facility. Additionally, Prof. Hugo Katus, who is recognized as one of the leading heart surgeons and clinicians worldwide, has agreed to be nominated for appointment to the Supervisory Board. These changes are intended to add relevant breadth of experience and independence to the uniQure Supervisory Board.
QURE: 25.17 (+0.08), ANGO: 17.74 (+0.13)
Ackman Short Keeps Looking Better As Herbalife Takes A Dive
at The Street - Mon Jan 05, 2:46PM CST
Voltari Corp (NASDAQ:VLTC), Kite Pharma Inc (NASDAQ:KITE) and Uniqure NV (NASDAQ:QURE) are approaching market close in the green this Monday. In the red are Laredo Petroleum Inc (NYSE:LPI), Herbali...
HLF: 42.72 (-0.45), QURE: 25.17 (+0.08), KITE: 59.98 (+0.20), VLTC: 0.85 (+0.02), LPI: 13.21 (+0.46)
uniQure N.V. (QURE) Jumps: Stock Adds 6.3% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 7:51AM CST
uniQure N.V. (QURE) was a big mover last session, as its shares rose over 6% on the day.
QURE: 25.17 (+0.08), ANIP: 62.93 (+0.99), ILMN: 187.62 (+0.45), AFFX: 12.86 (+0.15)
uniQure to Present at the Oppenheimer 25th Healthcare Conference - NYC
GlobeNewswire - Fri Dec 05, 4:09AM CST
uniQure N.V. (Nasdaq: QURE), a leader in human gene therapy, today announced that its management will present at the Oppenheimer 25th Healthcare Conference - NYC, to be held December 10-11, 2014, at The Crowne Plaza Hotel in New York City, NY, USA.
QURE: 25.17 (+0.08)
uniQure reports Q3 results
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 7:37AM CST
QURE: 25.17 (+0.08)
